PHP61 Geographical Inequalities in the Access to and Utilization of Home Care (Nursing) Services in Hungary  by Cs. Horváth, Z. et al.
 VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  A463
PHP59
WHicH Are tHe Attitudes of PrimAry HeAltH services users 
concerning cost sHAring meAsures in A Period of economic crisis in 
greece?
Siskou O.1, Galanis P.1, Kouli E.1, Tsavalias K.1, Kaitelidou D.1, Theodorou M.2, Prezerakos P.3, 
Spinthouri M.1, Vafeiadis J.4, Kalogeropoulou M.1
1National and Kapodistrian University of Athens, Athens, Greece, 2Open University of Cyprus, 
Latsia, Cyprus, 3University of Peloponnese, Sparta, Greece, 4National Organization for the 
Provision of Health Services (EOPYY), Marousi, Greece
Objectives: To identify the extent to which patients accept the measure of cost 
sharing fee (5€ ) in public primary health care units (health centers and hospitals’ 
outpatient departments) as well as to investigate whether patients perceive the 
potential benefits of the measure for the quality improvement of provided health 
care. MethOds: The study population consisted of 1260 people, who used public 
primary health care units. A structured questionnaire was used, including ques-
tions for patients’ demographic characteristics, their attitude regarding the cost 
sharing mechanism (compliance, perception of the benefits for health services 
upgrade etc), and their level of satisfaction with the provided services. Results: 
The implementation of cost sharing mechanism was positively accepted by 30% 
of respondents. Approximately 90% of the respondents, who expressed positive 
opinion for the implementation of the mechanism, considered that it would provide 
financial support to health units. Among the respondents who expressed negative 
opinion for the measure, 95% believed that health services should be public and free 
for everyone, 83% expressed lack of confidence that the measure aims at upgrading 
the provided services, 78% believed that the insurance contributions they already 
pay are high and 67% stated no financial comfort. The negative opinions were more 
frequent among people with lower socio-economic profile and those who have used 
health centers (p< 0.06). Respondents with higher socio-economic profile, coming 
from urban areas and respondents who were very satisfied with health services 
had statistically significantly greater possibility to express positive opinion for the 
measure. cOnclusiOns: Low socio-economic profile is negatively associated with 
the acceptance of the implementation of cost sharing mechanism, while high satis-
faction with services is positively associated with the acceptance of the mechanism. 
The majority of those, who expressed positive opinion for the measure, consider it 
as a contribution to the enhancement of health services.
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Objectives: Financial incentives or Pay-for-Performance (P4P) have become a 
common approach to improve the quality in health care. Although the effective-
ness is mixed, more and more P4P initiatives are implemented. Besides the desired 
effects of quality improvement, a growing number of evaluations show that finan-
cial incentives lead to unintended consequences. Therefore this study analyses 
negative effects of P4P. MethOds: On the basis of a systematic review of system-
atic reviews regarding P4P in health care (nine systematic reviews included that 
evaluate 75 different primary studies; Methodological quality assessment using the 
AMSTAR checklist) an additional hand search was conducted to identify evidence of 
unintended consequences of P4P. Results: Both theory and evidence of financial 
incentives demonstrate the potential of negative effects. Risk selection is identified 
in six reviews: Patients could get selected due to their severity of illness in order 
to achieve quality targets with minimum effort (cherry picking); Physicians will 
focus on indicators or aspects of care that are linked to payments (teaching to the 
test). Focussing on incentivized indicators could lead to quality decrease in non-
incentivized indicators (negative spillover effects), assessed in four reviews. Five 
reviews show that physicians could game the P4P program by reporting incorrect 
results and therefore increase their payments (gaming). Furthermore, improvements 
can be the result of better documentation and not actual quality improvements (four 
reviews). Finally one review identified crowding out of intrinsic motivation due to 
financial incentives. cOnclusiOns: The available evidence shows that P4P can 
result in unintended consequences. Evaluations of P4P should include these effects 
in order to assess an overall effect and thereby determine the effectiveness of P4P. 
To avoid negative effects it is important to consider the potential of unintended 
consequences and develop appropriate solutions.
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Objectives: Home care (nursing) was introduced into the Hungarian basic health 
insurance package in 1996. The aim of our study is to analyze the geographical ine-
qualities in the access to and utilization of that services in Hungary. MethOds: Data 
were derived from the nationwide administrative dataset of the National Health 
Insurance Fund Administration (OEP), the only health care financing agency in 
Hungary. The geographical inequalities in home care (nursing) services were meas-
ured by the number patients, visits and reimbursement according to 20 Hungarian 
counties. We analyzed the year 2011. Results: The national average number of 
patients was 51 patients / 10000 population. We found the highest patient number 
in county Zala (67), Jász-Nagykun-Szolnok (63) and Baranya (62), while the lowest 
number in county Békés (43), Somogy (43) and Szabolcs-Szatmár-Bereg (28). The 
national average number of home visits was 1193 visits / 10000 population. We found 
the highest number of visits in county Nógrád (1494), Tolna (1385) and Fejér (1377), 
while the lowest number in county Somogy (1138), Csongrád (1106) and Szabolcs-
Szatmár-Bereg (678). The national average of reimbursement per patient was 65345 
Objectives: Electronic-prescribing (E-prescribing) in comparison to manual (“by 
hand”) generation, transmission and filling of prescriptions is thought to substan-
tially lower the risks of inaccuracy and therefore reduce associated health care 
resource use and costs. The purpose of this work is to describe the current state of 
e-prescribing systems implementation in Denmark, Germany, Italy, Poland, United 
Kingdom (UK) and United States (USA), and to assess present evidence of its influ-
ence on health care. MethOds: A systematic review supplemented by additional 
hand-search was conducted to find relevant articles. Medline, Embase, The Cochrane 
Library and Scopus were searched. Quality was assessed on the basis of PRISMA, 
MOOSE and STROBE checklists and West 2002 recommendations. Results: Thirty-
one relevant full texts were identified during systematic review, and then as a result 
of hand-search, 5 publications were added. E-prescribing varies considerably across 
these countries. It is currently voluntary in Germany, Italy and United States. In 
United Kingdom the system is implemented except for electronic signature. In 
Denmark e-prescribing is mandatory for primary care providers. Model implemen-
tation in Poland is expected to take place in 2014. Of these 36 sources, 4 articles 
assessing e-prescribing were of the highest quality, as judged using the assessment 
methods. Positive influence on medical visits frequency, quality of care, patient 
satisfaction, prescription errors frequency, and prescriber-pharmacy-patient com-
munication was described in literature; most studies were conducted in the UK 
and USA. No data about effects of implementation for Germany, Italy, Denmark and 
Poland were found. cOnclusiOns: Implementation of e-prescribing is in process 
in the majority of described countries. Although few studies exist that definitely 
demonstrate positive impact of e-prescribing on health care, gathered papers do 
indicate positive effects. More comprehensive assessments would be valuable in 
showing the attributes of e-prescribing that are most valuable, and those that may 
be strengthened.
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Objectives: To review, describe and assess models of drug safety monitoring in 
England, Poland, Italy, Germany, Denmark and in the United States and prepare 
recommendations useful in health authorities decision-making process. MethOds: 
A review of documents, materials and information published on national medicines 
agencies as well as WHO’s statements was conducted, supplemented by hand-
search of literature. Results: The advantages and disadvantages of described phar-
macovigilance schemes in selected countries has been discussed. The gathered data, 
related i.a. to the level of adverse drug reaction reporting in different countries, was 
used to assess the efficacy of national reporting process. Moreover our research 
allowed us to value the formula of pharmacovigilance schemes as well as the atti-
tudes of health care professionals and patients towards it. cOnclusiOns: Although 
the majority of compared countries are European Union members bound to respect 
the same acts of European law, there are still many significant differences met in 
Pharmacovigilance practice reflecting in the level of adverse reaction reporting. 
These differences may be found as the treatment of newly registered medicines, 
data availability and transparency of procedures within the agencies or the relation-
ship between health authorities and potential reporters. A set of recommendations 
has been prepared related to special treatment of new medicines, creating aware-
ness of importance of pharmacovigilance in health care (hospitals, pharmacies), 
changing the attitude to risk aspects, transparency of safety monitoring practice 
and patients’ enrollment. The implication of our proposals could help to amend the 
pharmacovigilance systems in all discussed countries.
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Objectives: To describe existing models of pharmaceutical care (PC) in England, 
Poland, Germany, Denmark, Italy and United States and to indicate similarities 
and specific attributes meant as differences (from the whole system point of view), 
identifying possibly promising solutions (promising means having preliminary or 
probably positive results described in found literature). MethOds: A systematic 
and non-systematic literature review in Medline, Embase, Scopus and the Cochrane 
Library was performed. Quality of publications was critically appraised. Results: 
The review identified 48 full texts. The majority of papers were of moderate quality 
(PRISMA, MOOSE or STROBE checklists) and intermediate consistency, coherence 
and strength (West 2002). In chosen countries differences in the definition of PC 
have been noticed and therefore often it is difficult to find similarities. Although in 
some countries like England and the US, PC is firmly established and comparable 
with one another, in other it is very heterogeneous. Mainly in Central and Eastern 
Europe (CEE), especially in Poland, it is offered to a very limited extent or only pilot 
implementations exist. Four types of PC models have been distinguished: Anglo-
Saxon, Scandinavian, German and Italian. Specific attribute of English PC is division 
into essential, advanced and enhanced services. American pharmacists provid-
ing this service must be highly specialized. Danish system focuses on identifying, 
solving and prevention of drug-related problems. In Germany family pharmacy 
concept emerged. Pivotal point of Italian system is hospital PC. Identified promis-
ing solutions found in some countries were i.a. Drug Utilization Review, disease 
management programs or medicines use review. cOnclusiOns: Identical PC con-
cept may be difficult to introduce in all EU Member States, due to differences in 
health systems. However, some identified, promising actions should be considered 
by decision makers and providers, as well as implementing PC to a sufficient extent 
in CEE countries.
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(100%), Abbott (100%), Bayer (83%), Gilead (80%), and Boehringer-Ingelheim (80%). 
The average time to receive a CDR recommendation varied from 170 days to 248 
days. The manufacturers with the fastest time to recommendation are GSK, Abbott, 
Roche, Boehringer-Ingelheim, and Watson. Time to reimbursement / formulary list-
ings in all provinces ranged from 123 days to 593 days. cOnclusiOns: This is the 
first analysis to describe the success rate of pharmaceutical manufacturers through 
the CDR. There appears to high variability in all the metrics that were measured and 
further research into the determinants of variability is warranted.
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Objectives: To investigate the impact of Medicare Part D on prescription utilization, 
health services utilization, and health care expenditures in the general Medicare 
population. MethOds: A retrospective analysis of Medicare beneficiaries (N= 32,228) 
was conducted using the Medical Expenditure Panel Survey 2002 to 2009 data. 
Multivariable quantile regression was used to estimate the following outcomes at 
the 25th, 50th, 75th, and 90th percentiles, adjusting for socio-demographic charac-
teristics: 1) number of prescription fills; 2) out-of-pocket (OOP) drug expenditures; 3) 
total drug expenditures; 4) OOP health care expenditures; 5) total health care expen-
ditures; 6) number of hospitalizations; and 7) number of emergency department 
(ED) visits between the pre-Part D (2002-2005) and post-Part D (2006-2009) periods. 
All expenditures were inflation-adjusted to 2009 dollars. Results: In the general 
Medicare population, Part D was associated with decreases in OOP drug expenditures 
(-25.7% to -33.6%; p< 0.0001) and OOP health care expenditures (-22.1% to -24.3%; 
p< 0.0001) across all percentiles. Part D was associated with increases in the number 
of prescription fills across all percentiles (5.8% to 8.4%; p< 0.0001) but only at the 
75th and 90th percentiles for increases in total drug expenditures (75th percentile: 
5.5%; 90th percentile: 10.2%; p< 0.0001). Part D was not associated with changes in 
total health care expenditures, hospitalizations, or ED visits in the general Medicare 
population. cOnclusiOns: Part D resulted in increases in medication utilization 
and reductions in OOP drug and OOP health care expenditures among Medicare 
beneficiaries, but was not associated with differences in total health care spending, 
hospitalizations, or ED visits.
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Objectives: The General Medical Services (GMS) scheme presently covers around 
40% of the Irish population and entitles them, inter alia, to free prescription drugs and 
appliances. This paper projects the effects of future changes in population, coverage, 
claims rates and average claims cost on GMS costs in Ireland. MethOds: Data on 
GMS coverage, claims rates and average cost per claim are drawn from the Primary 
Care Reimbursement Service (PCRS) and combined with Central Statistics Office (CSO) 
(Regional and National Population Projections through to 2026). A Monte Carlo Model 
is used to simulate the effects demographic change (by region, age, gender, coverage, 
claims rates and average claims cost) will have on GMS prescribing costs in 2016, 
2021 and 2026 under different scenarios. Results: A total of 100,000 Monte Carlo 
simulations indicate that GMS medicines costs could rise to € 1.9bn by 2026 and will 
likely fall in the € 1.7bn to € 2.3bn region. Population is projected to grow by 32% by 
2026 and by 96% for the over 70s. The Eastern region is estimated to grow by 3% over 
the lifetime of the projections at the expense of most other regions. The Monte Carlo 
simulations project that females will be a bigger driver of GMS costs than males. Those 
aged 70 and over and children under 12 will be significant drivers of GMS costs with 
the impending demographic changes. cOnclusiOns: GMS coverage is increasing 
in tandem with falling public health budgets and poses a threat going forward to the 
sustainability and funding of the GMS scheme. Our projections and simulations map 
the likely evolution of GMS cost, given existing policies and demographic trends.
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Objectives: Ireland currently has one of the highest levels of public drug spending 
per capita in Europe. As budget retrenchment efforts continue, publically-funded 
drug schemes such as the General Medical Scheme have been the subject of several 
initiatives to reduce costs in recent years. However, little is known about the regional 
and socio-demographic factors that may influence variations in prescribing across 
the state. The objective of this study was to identify these factors. MethOds: Using 
a 192,000-strong sample of PCRS data drawn from monthly GMS returns for 2007, 
we constructed an ANOVA model that included the main effects of age, gender and 
region together with their second order and third order interactive terms in an 
interactive effects regression model examining the role of gender, age category and 
region of residence in explaining variation in prescribing costs for Ireland. Results: 
Mean cost per person per month was € 102. Men were on average more expensive 
than women (€ 109 vs. € 94) and cost increased with age group (€ 34 for those 0-12yrs 
and € 169 for those over 75). The most expensive region was the Midlands HSE region 
(€ 103) while the North West (€ 90) was the least costly. Most of the variation in pre-
scribing costs was explained by age, though the relationship between prescribing 
cost and age category was not constant. A significant three-way interaction was 
found between age category, gender and region. cOnclusiOns: The regional and 
Hungarian Forint (HUF) or 234 Euro (EUR) / patient. We found the highest reimburse-
ment per patient in county Nógrád (87879 HUF, 315 EUR), Fejér (80851 HUF, 290 EUR) 
and Békés (77643 HUF, 278 EUR), while the lowest reimbursement county Budapest 
(58859 HUF, 211 EUR), Jász-Nagykun-Szolnok (55757 HUF, 200 EUR) and Zala (54924 HUF, 
197 EUR). cOnclusiOns: We found significant differences measured by all the three 
indicators in home care (nursing) services in Hungary. Our results revealed that there 
are important inequalities both in the access to and utilization of home care services.
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Objectives: General population EQ-5D health surveys have been accumulated 
in the EuroQol Group’s archive over the past two decades. Using the database as a 
source of standardized measure of self-reported health, the objective was to esti-
mate the level of health (EQ-5D population norms) and the distribution of health 
within populations along socio-demographic characteristics. MethOds: Analyses 
captured EQ-5D data on 163,838 individuals from 18 countries with nationally repre-
sentative population surveys. Descriptive statistics were used to provide EQ-5D-3L 
population norms by age and gender categories for EQ VAS, EQ-5D index values, 
and for the 5 dimensions for each country. Odds ratios and the health concentra-
tion index methodology were used in the socio-demographic analysis of EQ-5D 
data. Results: The mean EQ-VAS rating varied from 71.1 to 83.7 and from 70.4 to 
83.3 across countries without and with age standardization, respectively. Statistically 
significant inequalities existed in all samples (p< 0.01) with the EQ-VAS based health 
concentration index varying from 0.090 to 0.157 across countries. Among the soci-
odemographic factors, age had generally the largest contributing share, while edu-
cation also had a consistent role in explaining lower levels of self-reported health. 
Among the 5 dimensions, usual activities and pain/discomfort were the highest 
contributors to overall inequalities in most countries. cOnclusiOns: EQ-5D norms 
can be used as reference data to compare patients with specific conditions and to 
assess the burden of the disease in question. Inequalities in self-assessed health 
exist in all countries with different social and cultural backgrounds, deserving the 
attention of policy makers within each country.
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Objectives: In Ukraine the pharmacovigilance system for adverse reactions is 
working. In 2008 was received 7,115, 2009 – 8291, 2010 – 8673, 2012- 11674 card-
reports of adverse reactions (AR) drugs. MoH conducted a detailed analysis of these 
reports found that 13% of them experienced serious adverse events, and 0.7% of the 
cards with the unexpected AR. MethOds: We analyzed the side effects depending 
on the ATC-group drugs. Results: We found that antimicrobial agents for sys-
temic use the largest number of reports received on AR (75.4%), which in most 
cases manifested anaphylactic AR. Further analysis showed that AR often were 
drugs (by INN): ceftriaxone (12.6%), amoxicillin in combination with clavulanic 
acid (8.0%), levofloxacin (6.3%). Among the cardiovascular drugs, reports AR often 
came on enalapril (10.0%), pentoxifylline (9.7%) and amlodipine (8.1%).Among the 
drugs affecting the nervous system, haloperidol (7.4%), metamizol sodium (7.4%) 
and paracetamol (7.0%). The analysis showed that the ratio of serious not serious 
AR under anti-neoplastic drugs and antiretroviral drugs is 1:2, anti-TB drugs - 1:3, 
and those affecting the cardiovascular system, gastrointestinal tract, respiratory 
system - under 1:9, 1 : 6, 1:6. Thus, the frequency of serious AR is much higher in 
the application of anti-neoplastic, anti-HIV and anti-TB drugs.The greatest risk 
AR was for children aged 28 days - 11 years, especially boys, and adults, especially 
women aged 46-60 years. cOnclusiOns: Results of the analysis of AR indicate 
that needed pharmaceutical care when dispensing antiretrovirals, anti-tuberculosis, 
anti-neoplastic drugs that meet the requirements of Good pharmacy practice in 
Ukraine. Implementation of training courses and programs for pharmacists on the 
subject of safe use of drugs to treat infectious diseases, tuberculosis and HIV / 
AIDS is essential. As well as acquiring skills pharmaceutical care and prevent AR 
in dispensing drugs to children and women 45-60 years.
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Objectives: The Canadian Common Drug Review (CDR) is a national HTA agency 
that has been in existence for 10 years. During this, the CDR has reviewed the 
clinical and cost-effectiveness of 188 drugs and provided 269 recommendations to 
the publically funded drug plans. Of all the drugs reviewed over the past 10 years, 
50.4% have received a positive recommendation and 49.6% have received a negative 
recommendation. The objective of this analysis was to describe the success rate of 
each pharmaceutical manufacturer in terms of type of recommendation, time to 
recommendation, and time to listing in the provincial formularies. MethOds: The 
CDR Tracker database was used to analyze all CDR drug reviews from 2003 to the end 
of 2012. There were a total of 189 reviews during this 10 year period. All manufactur-
ers that had three or more submissions with CDR were included in the analysis; 
29 companies met this criterion. Results: Of the 189 reviews and 29 companies 
analyzed, the positive recommendation rates ranged from 100% to 17%. The top 5 
most successful manufactures in terms of positive recommendations were Roche 
